Researchers at Baylor College of Medicine and the University of Michigan conducted a phase I pilot study to assess the feasibility of using potato starch as a dietary intervention to modify the gut microbiome in bone marrow ...
Oct 19, 2023
0
72
In a first-of-its-kind study, researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years. Of those monitored, 2,038 received the booster ...
Dec 28, 2022
0
108
A groundbreaking new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumor cells through the use of nanobiologics, tiny materials ...
Oct 29, 2020
0
236
As a growing number of older adults are experimenting with cannabis to help alleviate chronic symptoms, a new University of California San Diego School of Medicine study has identified a sharp increase in cannabis-related ...
Jan 9, 2023
1
2
A TikTok influencer grins into the camera. Shirtless, his bronzed skin contrasts on a light background.
Jan 30, 2023
0
2
(HealthDay)—In a small study from France, an immune-dampening drug used by people battling rheumatoid arthritis showed promise in patients hospitalized with severe COVID-19.
Jul 24, 2020
0
7
Metformin,a common drug used to treat type 2 diabetes, is often used during pregnancy where the mother suffers from polycystic ovary syndrome (PCOS). A new study from the Norwegian University of Science and Technology (NTNU) ...
Mar 27, 2019
0
71
A promising therapy for a range of brain diseases involves antisense oligonucleotides (ASOs)—specialized molecules that can modulate RNA and alter protein production—directly injected into the cerebrospinal fluid, in ...
Mar 13, 2023
0
575
Chlorthalidone, the guideline-recommended diuretic for lowering blood pressure, causes more serious side effects than hydrochlorothiazide, a similarly effective diuretic, according to a new study led by researchers at Columbia ...
Feb 17, 2020
0
134
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
